Sattva S Neelapu

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report
    Sattva S Neelapu
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Clin Lymphoma 6:61-4. 2005
  2. ncbi request reprint BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma
    Seung Tae Lee
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, Division of Cancer Medicine, 1515 Holcombe Blvd, Unit 903, Houston, TX, 77030 USA
    Expert Opin Biol Ther 7:113-22. 2007
  3. pmc Therapy of newly diagnosed follicular lymphoma
    Jason R Westin
    University of Texas MD Anderson Cancer Center Houston, TX, USA
    Front Oncol 2:188. 2012
  4. pmc Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula
    Jason R Westin
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Case Report Med 2012:457908. 2012
  5. ncbi request reprint Therapeutic lymphoma vaccines: importance of T-cell immunity
    Sattva S Neelapu
    UT MD Anderson Cancer Center, Department of Lymphoma Myeloma, Unit 903, 7455 Fannin, Houston, TX 77054, USA
    Expert Rev Vaccines 5:381-94. 2006
  6. ncbi request reprint Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Cancer Res 10:8309-17. 2004
  7. pmc A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma
    Sattva S Neelapu
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:5160-3. 2007
  8. doi request reprint Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity
    Hong Qin
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:4142-9. 2009
  9. pmc Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
    Jason R Westin
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 15:69-77. 2014
  10. ncbi request reprint Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Med 11:986-91. 2005

Detail Information

Publications55

  1. ncbi request reprint Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report
    Sattva S Neelapu
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Clin Lymphoma 6:61-4. 2005
  2. ncbi request reprint BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma
    Seung Tae Lee
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, Division of Cancer Medicine, 1515 Holcombe Blvd, Unit 903, Houston, TX, 77030 USA
    Expert Opin Biol Ther 7:113-22. 2007
    ..A randomized, double-blind, Phase III clinical trial is ongoing to definitively determine the clinical benefit of BiovaxID plus granulocyte-macrophage colony-stimulating factor vaccination in patients with follicular lymphoma...
  3. pmc Therapy of newly diagnosed follicular lymphoma
    Jason R Westin
    University of Texas MD Anderson Cancer Center Houston, TX, USA
    Front Oncol 2:188. 2012
    ..This review discusses the indications for treatment, risk stratification systems, treatment options with supporting clinical trial data, and expected therapeutic outcomes in newly diagnosed follicular lymphoma...
  4. pmc Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula
    Jason R Westin
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Case Report Med 2012:457908. 2012
    ..Even in a patient with significant Hodgkin-lymphoma-related sequelae, standard therapy can result in excellent long-term outcomes...
  5. ncbi request reprint Therapeutic lymphoma vaccines: importance of T-cell immunity
    Sattva S Neelapu
    UT MD Anderson Cancer Center, Department of Lymphoma Myeloma, Unit 903, 7455 Fannin, Houston, TX 77054, USA
    Expert Rev Vaccines 5:381-94. 2006
    ....
  6. ncbi request reprint Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Cancer Res 10:8309-17. 2004
    ..In the present study, we evaluated the safety and immunogenicity of this vaccine in follicular lymphoma patients...
  7. pmc A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma
    Sattva S Neelapu
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:5160-3. 2007
    ..Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined...
  8. doi request reprint Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity
    Hong Qin
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:4142-9. 2009
    ..These studies also challenge the paradigm that antibody responses are the primary of idiotype-specific antitumor effects and support the optimization of idiotype vaccines designed to induce primarily T-cell immunity...
  9. pmc Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
    Jason R Westin
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 15:69-77. 2014
    ..We did this phase 2 trial to investigate the activity of pidilizumab, a humanised anti-PD1 monoclonal antibody, with rituximab in patients with relapsed follicular lymphoma...
  10. ncbi request reprint Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Med 11:986-91. 2005
    ..Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses...
  11. pmc A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones
    Seung Tae Lee
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol Methods 331:13-26. 2008
    ..The method was simple, efficient, and reproducible, and may have potential application for the development of adoptive immunotherapeutic strategies...
  12. doi request reprint The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
    Dai Chihara
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol . 2016
    ..Further research for novel therapeutic approaches with higher efficacy and better safety profile are needed...
  13. pmc Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
    Felipe Samaniego
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 169:814-23. 2015
    ..This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age. ..
  14. ncbi request reprint Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models
    Kuichun Zhu
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Vaccine 25:7955-61. 2007
    ..We conclude that survivin DNA vaccine generated specific antitumor effects with increased lymphocyte infiltration at the tumor sites...
  15. pmc Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:6373-8. 2012
    ..The addition of (90)Y to the conditioning regimen appears to be effective in patients with chemorefractory disease. This trial was registered at www.clinicaltrials.gov as NCT00048737...
  16. doi request reprint Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
    Dai Chihara
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 171:509-16. 2015
    ..This study was registered at www.clinicaltrials.gov as #NCT00290433. ..
  17. pmc Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma
    Qingshan Yang
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 120:3491-500. 2012
    ..Genetic knockdown of Pim-1/Pim-2 affected similar proteins in MCL cell lines. Collectively these data demonstrate Pim kinases as therapeutic targets in MCL...
  18. doi request reprint Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:716-23. 2012
    ....
  19. pmc Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes
    Jinsheng Weng
    Department of Lymphoma and Myeloma, Stem Cell Transplantation and Cellular Therapy, and Center for Cancer Immunology Research, MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:5945-52. 2011
    ..However, epitopes derived from Id that stimulate human CD8(+) T-cell immunity are incompletely characterized...
  20. doi request reprint Identification of human idiotype-specific T cells in lymphoma and myeloma
    Jinsheng Weng
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Top Microbiol Immunol 344:193-210. 2011
    ..Finally, we propose new directions in the generation of idiotype-specific T cells for tumor therapy...
  21. doi request reprint Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines
    Hong Qin
    Department of Lymphoma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Vaccine 28:7970-8. 2010
    ..This novel mechanism of immune potentiation may be exploited for development of adjuvants for genetic vaccines against infectious pathogens and cancer...
  22. doi request reprint Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma
    Dai Chihara
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 122:3145-3151. 2016
    ..The number of elderly patients with diffuse large B-cell lymphoma (DLBCL) in our aging society continues to rise, although the optimal management of very elderly patients with DLBCL is unknown...
  23. pmc Targeting Wnt pathway in mantle cell lymphoma-initiating cells
    Rohit Mathur
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    J Hematol Oncol 8:63. 2015
    ..Cancer stem cell-related pathways such as Wnt could be responsible for their maintenance and survival...
  24. pmc Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
    Nathan H Fowler
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 15:1311-8. 2014
    ..We assessed the efficacy and safety of lenalidomide plus rituximab in patients with untreated, advanced stage indolent non-Hodgkin lymphoma...
  25. pmc Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 15:152-8. 2015
    ....
  26. pmc Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment
    Seema Rawal
    Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 190:6681-93. 2013
    ..Our results provide novel insights into the cross talk among TFH, tumor cells, and Tregs in FL, and offer potential targets for development of therapeutic strategies to overcome immune evasion...
  27. ncbi request reprint Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo
    Arya Biragyn
    Laboratory of Immunology, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
    Blood 104:1961-9. 2004
    ....
  28. pmc Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen
    Soung Chul Cha
    Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 190:4887-98. 2013
    ..These findings may lead to a better understanding of the biology and natural history of FL and other B cell malignancies...
  29. pmc TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas
    Jinsheng Weng
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:1613-23. 2012
    ....
  30. doi request reprint Vaccination strategies in follicular lymphoma
    Shibichakravarthy Kannan
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 903, Houston, TX 77030, USA
    Curr Hematol Malig Rep 4:189-95. 2009
    ..This review focuses on the results of these idiotype vaccine trials and discusses potential strategies to enhance the efficacy of vaccines in the future...
  31. pmc Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials
    Hyun Jun Park
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 142:179-91. 2008
    ..This review will focus on the development of Id vaccines before and after the introduction of rituximab for the treatment of B-cell NHL and also discuss potential strategies to enhance the efficacy of active immunotherapy in the future...
  32. pmc Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  33. pmc Targeting B-cell malignancies through human B-cell receptor specific CD4+ T cells
    Jinsheng Weng
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
    Oncoimmunology 5:e1232220. 2016
    ....
  34. pmc Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 169:689-93. 2015
    ..This data demonstrates the feasibility of detecting circulating tumour-specific sequences, creating an unprecedented opportunity to optimize the future treatment and monitoring strategies for patients with CHL. ..
  35. pmc Therapeutic vaccine for lymphoma
    Seung Tae Lee
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Yonsei Med J 48:1-10. 2007
    ..It is hoped that immunotherapeutic agents, used in tandem or in combination, may in the future allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies...
  36. pmc Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma
    Stephen J Schuster
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 29:2787-94. 2011
    ..To determine the clinical benefit of this vaccine, we conducted a double-blind multicenter controlled phase III trial...
  37. ncbi request reprint Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
    Qingshan Yang
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res . 2016
    ..We hypothesized that PI3Kδ-isoform inhibition by idelalisib should also affect gene transcription and protein translation...
  38. pmc Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells
    Haiyan S Li
    Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Sci Signal 9:ra94. 2016
    ..Thus, inhibiting STAT3 or overexpressing ID2 selectively in DCs may improve the efficiency of DC vaccines in cancer therapy. ..
  39. pmc Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma
    Kui Shin Voo
    Department of Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX
    Int J Cancer 135:2834-46. 2014
    ....
  40. doi request reprint 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
    Felipe Samaniego
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 167:207-13. 2014
    ..90) YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response...
  41. pmc Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma
    Qingshan Yang
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
    Clin Lymphoma Myeloma Leuk 13:S355-62. 2013
    ..Bendamustine is an alkylating chemotherapeutic agent approved for use in B-cell lymphoma that is known to induce DNA damage and initiate response to repair...
  42. pmc Essential role of TAK1 in regulating mantle cell lymphoma survival
    Daniela Buglio
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 120:347-55. 2012
    ..Collectively, our data demonstrate an essential role for TAK1 in regulating critical survival mechanisms in lymphoma and suggest that it may serve as a therapeutic target...
  43. ncbi request reprint Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion
    Larry W Kwak
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Semin Oncol 31:37-46. 2004
    ..Donor immunization with myeloma idiotype protein in the setting of a nonmyeloablative SCT may represent a novel strategy for the treatment of myeloma...
  44. pmc Prospective isolation of clonogenic mantle cell lymphoma-initiating cells
    Zheng Chen
    Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases IMM, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Stem Cell Res 5:212-25. 2010
    ....
  45. ncbi request reprint Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines
    Pier Adelchi Ruffini
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702 1201, USA
    Haematologica 87:989-1001. 2002
    ....
  46. pmc Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment
    Han Zhang
    Center for Stem Cell and Regenerative Disease, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases IMM, The University of Texas Health Science Center at Houston, Houston, Texas, USA
    Oncotarget 7:14350-65. 2016
    ..Inhibiting autophagy will be an effective adjuvant therapy for LDE225 in MCL, especially for advanced MCL patients with bone marrow involvement. ..
  47. pmc Role of the tumor microenvironment in mature B-cell lymphoid malignancies
    Nathan H Fowler
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 101:531-40. 2016
    ....
  48. doi request reprint Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy
    Chelsea C Pinnix
    Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
    JAMA Oncol 2:1065-9. 2016
    ..The management of lymphoma diagnosed during pregnancy is controversial and has been guided largely by findings from case reports and small series...
  49. doi request reprint Double hit lymphoma: the MD Anderson Cancer Center clinical experience
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 166:891-901. 2014
    ..Further research is needed to identify predictive and/or targetable biological markers and novel therapeutic approaches for DHL patients. ..
  50. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
    ..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...
  51. pmc 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma
    Jennifer B Dennison
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:5622-30. 2010
    ..We conclude that 8-NH(2)-Ado is efficacious in preclinical models of MCL and inhibits signaling of Akt/mTOR and Erk pathways...
  52. pmc IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay
    Jinsheng Weng
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
    Oncoimmunology 5:e1237327. 2016
    ..Thus, our study elucidates a new mechanism for IL-15 in the regulation of STAT signaling pathways and CD8+ T-cell senescence...
  53. doi request reprint Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Chan Yoon Cheah
    Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Curr Opin Oncol 27:384-91. 2015
    ..This review provides a timely overview of the biology and function of the PD-1 pathway and discusses the rationale for therapeutic inhibition of this pathway in lymphoma...
  54. pmc Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
    Aloke Sarkar
    Department of Experimental Therapeutics, The University of Texas Health Science Center, Houston, Texas, USA
    Oncotarget 7:3461-76. 2016
    ..This study underscores the first genetic evidence that B-PAC-1 driven apoptosis is mediated via Zn chelation. ..
  55. pmc A novel proteoliposomal vaccine elicits potent antitumor immunity in mice
    Mircea C Popescu
    XEME Biopharma, Plainsboro, NJ 08536, USA
    Blood 109:5407-10. 2007
    ..The increased potency justifies testing similar patient-specific human vaccines prepared using extracts from primary tumor samples...